Abstract: Certain embodiments of the present technology described herein relate to detecting atrial oversensing, characterizing atrial oversensing, determining when atrial oversensing is likely to occur, and or reducing the chance of atrial oversensing occurring. Some such embodiments characterize and/or avoid atrial oversensing.

Abstract: The present disclosure provides a graphical user interface (GUI) arranged to convey information related to the IVUS images and lesion assessment and provide for the user to manipulate the information. The GUIs can be generated to include a cross-section view without assessments post recording of IVUS images and to depict assessments after navigation through frames of the IVUS images.

Abstract: A display substrate including a base substrate and a plurality of pixel units on the base substrate. Each pixel unit includes: a plurality of sub-pixels and at least one scanning line. The plurality of sub-pixels are arranged sequentially in a first direction, each sub-pixels includes a sub-pixel driving circuit and a light-emitting element, and the sub-pixel driving circuit is coupled to the light-emitting element. Each scanning line includes a first scanning conductive layer and a second scanning conductive layer arranged in a laminated manner, the first scanning conductive layer is coupled to the second scanning conductive layer, the first scanning conductive layer includes at least a portion extending in the first direction, and the first scanning conductive layer is coupled to a plurality of sub-pixel driving circuits in the plurality of sub-pixels.

Abstract: Building blocks for a smart device such as a thermostat include a user interface (UI) unit and a terminal (TML) unit. A UI unit may support one or more input data from a user and/or sensors and/or one or more control terminals. The UI unit may process each input datum or a combination of the input data, generate a control signal to one or more control terminals based on the processing, and send the control signal to one or more control terminals over a communication channel. A terminal unit, which may consist of one or more control terminals, transforms the received control signal into one or more controls to one or more associated environmental generators. One or more UI units may control one or more controlled apparatuses in conjunction with a mobile app to allow a unified user experience.

Abstract: Building blocks for a smart device such as a thermostat include a user interface (UI) unit and a terminal (TML) unit. A UI unit may support one or more input data from a user and/or sensors and/or one or more control terminals. The UI unit may process each input datum or a combination of the input data, generate a control signal to one or more control terminals based on the processing, and send the control signal to one or more control terminals over a communication channel. A terminal unit, which may consist of one or more control terminals, transforms the received control signal into one or more controls to one or more associated environmental generators. One or more UI units may control one or more controlled apparatuses in conjunction with a mobile app to allow a unified user experience.

Abstract: Building blocks for a smart device such as a thermostat include a user interface (UI) unit and a terminal (TML) unit. A UI unit may support one or more input data from a user and/or sensors and/or one or more control terminals. The UI unit may process each input datum or a combination of the input data, generate a control signal to one or more control terminals based on the processing, and send the control signal to one or more control terminals over a communication channel. A terminal unit, which may consist of one or more control terminals, transforms the received control signal into one or more controls to one or more associated environmental generators. One or more UI units may control one or more controlled apparatuses in conjunction with a mobile app to allow a unified user experience.

Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.

Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.

Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.

Abstract: The present invention is a module testing tool for Web services. In one embodiment, the present invention automates the testing of Web services that use SOAP as a wire protocol and HTTP as a transport protocol. The invention provides an easy interface for exercising Web services and testing their functionality. The invention helps users confirm the responses to SOAP messages with such features as fault detection, textual comparisons, XML validation by DTDs or XML Schemas, and the ability to express and flag complex patterns in XML. The invention lets the users validate responses that require application-specific verification (such as business logic validation) by plugging in their own code. It also provides the capability to perform regression testing of web services. The invention can automatically creates regression test controls from SOAP Client responses, or users can create their own regression tests.

Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.